On the road to biological blood diagnosis of Alzheimer's disease? Vers un diagnostic biologique sanguin de la maladie d Alzheimer ?
The growing number of people suffering from Alzheimer s disease (AD) represents a major public health problem. The diagnosis of AD is multidisciplinary and involves the use of amyloid and tau biomarkers measured in cerebrospinal fluid. Recent advances in analytical techniques now allow us to measure...
| Autores: | , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | francés |
| OAI Identifier: | oai:ddd.uab.cat:306341 |
| Acceso en línea: | https://ddd.uab.cat/record/306341 https://dx.doi.org/urn:doi:10.1051/medsci/2024037 |
| Access Level: | acceso abierto |
| Palabra clave: | Alzheimer Disease Amyloid beta-Peptides Biomarkers Diagnosis, Differential Humans Tau Proteins |
| Sumario: | The growing number of people suffering from Alzheimer s disease (AD) represents a major public health problem. The diagnosis of AD is multidisciplinary and involves the use of amyloid and tau biomarkers measured in cerebrospinal fluid. Recent advances in analytical techniques now allow us to measure these biomarkers in blood. Blood biomarkers offer particularly promising potential for early, minimally invasive detection of AD, as well as for differential diagnosis of dementia and patient follow-up. The aim of this review is to provide an overview of current and candidate blood biomarkers for AD, their informative value, and their potential to be integrated into clinical practice in the near future. |
|---|